Serina Granted Until July 9, 2027 to Restore NYSE Listing Compliance
NYSE American accepted Serina Therapeutics’ compliance plan after the biotech reported shareholders’ equity of $1.6m and losses in three of four recent fiscal years. The company now has until July 9, 2027 to meet listing standards while maintaining its NYSE American listing under quarterly monitoring.
1. Compliance Plan Acceptance
Serina Therapeutics received formal acceptance of its continued listing compliance plan from the NYSE American, ensuring its common stock will remain listed while the company works to meet required standards.
2. Non-Compliance Background
The company had been flagged for non-compliance after reporting shareholders’ equity of $1.6 million and recording losses in three of its four most recent fiscal years ended December 31, 2024.
3. Cure Period and Monitoring
Serina has until July 9, 2027 to regain conformity with Sections 1003(a)(i) or 1003(a)(ii) of the NYSE American Company Guide, with quarterly monitoring to track progress; failure to comply will trigger delisting proceedings.